Document Detail


Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program.
MedLine Citation:
PMID:  10474087     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: This study was designed to review the incidence of adverse events during nearly 20,000 apheresis procedures over a 4-year period in a hospital-based program. METHODS: Data were obtained from a review of: (1) apheresis adverse event forms (2) hospital or emergency room medical records (3) the databank for donor and procedure-related variables. Adverse events during or after the apheresis procedures were analyzed according to the following categories: (1) complications related to citrate toxicity; (2) hypotensive or vasovagal episodes; (3) complications or symptoms consistent with coronary ischemia; (4) complications related to percutaneous needle insertion, and (5) miscellaneous procedure-related events or nonspecific symptoms. Serious adverse events were categorized as persistent or severe hemodynamic changes as well as other events that required further medical evaluation. RESULTS: Of 19,736 apheresis procedures, 159 (0.81%) were associated with adverse events. In 2,376 first-time donations, 26 (1.09%) developed adverse events compared to 133 (0.77%) of 17,360 repeat procedures (p = 0.10). Seventy (0.35%) of 159 donation-related adverse events involved hemodynamic or citrate-related complications and 73 (0.37%) involved venipuncture-related complications, of which 2 required subsequent neurologic consultation. The remaining 23 (0. 12%) adverse events involved procedure-related, nonspecific complications. Forty-seven (0.24%) of the 19,736 apheresis procedures were associated with serious adverse events (SAEs). Seven of these serious adverse events required admission to an emergency department, and 2 required hospitalization for further evaluation. Multivariate analysis revealed that apheresis machine model, donor gender and weight, the concomitant harvesting of plasma, the frequency of donation, and citrate-related symptoms (e.g. paresthesias) were independently associated with severe hypotensive reactions. CONCLUSIONS: Apheresis procedures have a 150-fold higher incidence of SAEs requiring hospitalization compared to whole blood donation. Identification of donors at risk for complications can facilitate modification of the apheresis procedure in order to reduce the likelihood of adverse events. Although our study did not demonstrate a cause-effect relationship between platelet donation and the development of acute coronary syndromes, underlying cardiovascular disease was detected in 2 donors during or after the apheresis who were otherwise asymptomatic.
Authors:
G J Despotis; L T Goodnough; M Dynis; D Baorto; E Spitznagel
Related Documents :
3787177 - Evidence that 111in-labelled platelets pool in the spleen, but not in the liver of norm...
24751477 - Plasma pentraxin-3 and coagulation and fibrinolysis variables during acute puumala hant...
15007427 - Biosynthetic pathways to dichloroimines; precursor incorporation studies on terpene met...
7205387 - Indium-111-labeled human platelets: improved method, efficacy, and evaluation.
22421217 - Thermal disaggregation of type b yeast hexokinase by indole derivatives: a mechanistic ...
187697 - Histamine modulation of eosinophil migration.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Vox sanguinis     Volume:  77     ISSN:  0042-9007     ISO Abbreviation:  Vox Sang.     Publication Date:  1999  
Date Detail:
Created Date:  1999-11-03     Completed Date:  1999-11-03     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0413606     Medline TA:  Vox Sang     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  24-32     Citation Subset:  IM    
Affiliation:
Washington University School of Medicine, St. Louis, MO 63110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Blood Donors*
Cardiovascular Diseases / blood
Citric Acid / poisoning
Coronary Disease / blood
Demography
Hospital Departments
Humans
Incidence
Male
Middle Aged
Missouri / epidemiology
Multivariate Analysis
Overdose
Plateletpheresis / adverse effects*
Retrospective Studies
Risk Factors
Chemical
Reg. No./Substance:
77-92-9/Citric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical evaluation of repeat apheresis donors in Japan.
Next Document:  Isoantibodies in immunoglobulin for intravenous use may cause erythrocyte sequestration.